Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, which allows for the precise reading and writing of DNA. Founded in 2013, the company targets multiple markets, including life sciences, industrial applications, information storage, nanotechnology, and DNA electronics. Its innovative approach is inspired by natural processes and focuses on producing long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner. The company boasts a strong executive and scientific team and holds an extensive intellectual property portfolio. It has garnered investments from various notable entities, highlighting its potential to advance products in industrial synthetic biology, personalized therapeutics, and precision diagnostics.
Maze Therapeutics is a biotechnology company based in South San Francisco, California, that specializes in the development of genetic modifier therapeutics. Founded in 2017 and formerly known as Modulus Therapeutics, the company is dedicated to translating genetic insights into innovative medicines. Maze Therapeutics utilizes a comprehensive approach that integrates large-scale human genetics data, functional genomics, and various drug discovery methodologies. This approach allows the company to identify modifier genes that offer protection against diseases, enhancing the understanding of target biology and informing drug development strategies. By leveraging these insights, Maze Therapeutics aims to facilitate the creation of novel therapies that can benefit patients.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Depixus SAS is a biotechnology company based in Paris, France, focused on the development of advanced technology for extracting genetic and epigenetic information from single molecules of DNA and RNA. Its main product, SIMDEQ™ (SIngle-molecule Magnetic DEtection and Quantification), enables fast, accurate, and cost-effective analysis of genomes and epigenetic modifications. Initially developed at École Normale Supérieure by prominent researchers, SIMDEQ™ allows for the identification, counting, full sequencing, and epityping of millions of individual DNA molecules with high precision. The technology has broad applications in the life sciences and medical fields, facilitating real-time analysis of biomolecular interactions and supporting researchers in uncovering new biological pathways, understanding disease mechanisms, and advancing precision medicine. With substantial validation completed, Depixus is moving towards platform optimization and commercialization to enhance its offerings in these critical areas.
Meiogenix SAS is a biotechnology company based in Paris, France, that specializes in developing breeding and genomic technologies aimed at unlocking the unexplored genetic diversity of organisms. Established in 2010, Meiogenix offers innovative solutions such as SpiX technology, which enhances homologous recombination in specific regions of the genome, and PhoeniX, a non-genetically modified method that facilitates meiotic recombination in hybrid diploid or polyploid yeast cells. These advancements enable the company to support the development of new products that address pressing global food and industrial challenges, expanding natural biodiversity through natural breeding techniques.
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.
Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.
Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
Genomatica, Inc. specializes in developing innovative manufacturing processes that convert renewable feedstocks into intermediate and basic chemicals. Utilizing its proprietary biotechnology platform, the company engineers microorganisms to facilitate fermentation-based production, focusing on a pipeline of 20 key chemicals, including butanediol and butadiene. Genomatica has established itself as a leader in bioengineering, aiming to foster a transition to sustainable materials. Its technology has gained recognition for commercializing processes for butanediol, used in biodegradable plastics and apparel, and butylene glycol, which is important in cosmetics and personal care products. The company is also advancing research in bio-nylon. Genomatica's achievements have been acknowledged through several awards, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol. Founded in 1998 and headquartered in San Diego, California, Genomatica focuses on enhancing the economics, sustainability, and performance of chemical production.
Hexagon Bio, Inc. is a biotechnology company based in Menlo Park, California, that specializes in mining genomic data from fungal genomes to develop targeted small molecule therapeutics for diseases with unmet medical needs. Founded in 2016, the company leverages a proprietary platform that integrates data science, synthetic biology, and automation to discover and engineer novel drugs. By focusing on evolutionarily refined molecules and their corresponding protein targets, Hexagon Bio aims to identify and develop new medicines from the global metagenome, ultimately striving to enhance patient outcomes through innovative therapeutic solutions.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.
Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.
Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company utilizes insights from its scientific founders to identify "switch sites," which are druggable regions that play a crucial role in regulating transcription factors and addressing disease-related mutations. Flare's innovative drug discovery efforts have led to a promising pipeline of drug programs targeting well-validated transcription factors, with an initial emphasis on precision oncology. The company's platform also holds potential for applications in neurology, rare genetic disorders, immunology, and inflammation, aiming to transform treatment approaches for various diseases.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Apton Biosystems, Inc., founded in 2012 and based in Pleasanton, California, operates within the biotechnology sector, focusing on innovative solutions for genetic analysis. The company has developed a high-throughput and low-cost sequencing platform that enhances the availability of genetic testing, facilitating biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems reimagines optical systems for sequencing and single-molecule protein detection, utilizing super-resolution technology to evaluate closely spaced molecules. This approach enables the healthcare sector to create well-defined nanostructures, addressing spatial challenges and advancing high-density sequencing and protein detection capabilities. Through these advancements, Apton Biosystems contributes to the fields of preventive health and precision medicine.
C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers an ultra-sensitive liquid biopsy assay that analyzes subtle changes in tumor DNA, enabling physicians to monitor treatment responses and detect disease recurrence or treatment failure significantly earlier than traditional methods. C2i Genomics employs a bio-platform approach applicable across various cancer types, facilitating the guidance of multiple treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, the company provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. Established in 2019, C2i Genomics is headquartered in New York, New York, with a research and development center located in Haifa, Israel.
Developer of a multi-omic platform designed to accelerate advancements in life science and medicine. The company's platform leverages DNA nanotechnology to develop solutions for biomedical applications by providing comprehensive data, thereby enabling doctors and patients to get an accurate and complete view of an individual's biochemistry with a single test.
Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
GeneMatters is a provider of genetic counseling services aimed at enhancing patient access to genetic insights through a scalable telehealth platform. Established in 2016 and based in Minneapolis, Minnesota, the company operates an online genetic counseling network that offers pre-test and full-service genetic counseling, as well as caregiving services. By collaborating with hospitals, health networks, clinics, academic research centers, and genetic testing labs, GeneMatters facilitates a better understanding of genetic family history, allowing users to make informed decisions based on their genetic tests. The company’s services are designed to integrate seamlessly with existing patient workflows, ensuring flexible staffing and clinical expertise are readily available.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers an ultra-sensitive liquid biopsy assay that analyzes subtle changes in tumor DNA, enabling physicians to monitor treatment responses and detect disease recurrence or treatment failure significantly earlier than traditional methods. C2i Genomics employs a bio-platform approach applicable across various cancer types, facilitating the guidance of multiple treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, the company provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. Established in 2019, C2i Genomics is headquartered in New York, New York, with a research and development center located in Haifa, Israel.
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. The company's focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits.
It was founded in 2018 and headquartered in Seattle, Washington.
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.
Maze Therapeutics is a biotechnology company based in South San Francisco, California, that specializes in the development of genetic modifier therapeutics. Founded in 2017 and formerly known as Modulus Therapeutics, the company is dedicated to translating genetic insights into innovative medicines. Maze Therapeutics utilizes a comprehensive approach that integrates large-scale human genetics data, functional genomics, and various drug discovery methodologies. This approach allows the company to identify modifier genes that offer protection against diseases, enhancing the understanding of target biology and informing drug development strategies. By leveraging these insights, Maze Therapeutics aims to facilitate the creation of novel therapies that can benefit patients.
Singular Bio, Inc. is a San Francisco-based company founded in 2012 that specializes in diagnostic testing for personalized medicine. The company has developed a cutting-edge technology for single molecule analysis of DNA, which offers exceptional sensitivity in detecting various common health conditions. Singular Bio's proprietary detection system aims to address the needs of high-volume healthcare testing, combining the accuracy of genetic analysis with the affordability and rapid results typically associated with screening tests. By leveraging advanced optics alongside custom molecular biology and chemistry, Singular Bio seeks to enhance healthcare accessibility and enable early detection of medical conditions for a broader population. As of mid-2019, Singular Bio operates as a subsidiary of Invitae Corporation.
Genomatica, Inc. specializes in developing innovative manufacturing processes that convert renewable feedstocks into intermediate and basic chemicals. Utilizing its proprietary biotechnology platform, the company engineers microorganisms to facilitate fermentation-based production, focusing on a pipeline of 20 key chemicals, including butanediol and butadiene. Genomatica has established itself as a leader in bioengineering, aiming to foster a transition to sustainable materials. Its technology has gained recognition for commercializing processes for butanediol, used in biodegradable plastics and apparel, and butylene glycol, which is important in cosmetics and personal care products. The company is also advancing research in bio-nylon. Genomatica's achievements have been acknowledged through several awards, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol. Founded in 1998 and headquartered in San Diego, California, Genomatica focuses on enhancing the economics, sustainability, and performance of chemical production.
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.
GenapSys, Inc. develops innovative DNA sequencing technologies for applied genomic testing and medical sequencing. The company's primary product, the GenapSys Sequencer, utilizes electrical-based detection for single nucleotide incorporations, facilitating sequencing in various laboratory settings and automating clonal amplification. GenapSys offers solutions for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. Additionally, the company seeks to collaborate with local health agencies and researchers to enhance access to sequencing insights, particularly for controlling and mitigating outbreaks. The compact and portable nature of the sequencer allows it to operate from standard power sources, making it suitable for deployment in hospitals, airports, and public transportation hubs to provide rapid results for virus samples. Founded in 2010, GenapSys is headquartered in Redwood City, California.
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.
Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead candidates, SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing Phase II trials for specific patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I trials for select advanced solid tumors. Syros employs a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to map gene regulatory circuits and modulate gene expression, positioning itself as a leader in gene control research. Additionally, Syros has established collaborations, including a target discovery agreement with Incyte Corporation focused on myeloproliferative neoplasms, and a licensing agreement with TMRC Co. Ltd. for tamibarotene's development and commercialization. Founded in 2011, Syros Pharmaceuticals aims to address significant unmet medical needs in oncology and beyond.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.
Fabric Genomics is making genomics-driven precision medicine a reality. We provide clinical decision support software that enables clinical labs, hospital systems and country-sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabric’s end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology. Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics.
Invitae is a genetic information company focused on integrating genetic testing into routine medical practice to enhance healthcare quality worldwide. It specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates a wide array of genetic tests into one platform, ensuring faster turnaround times and lower costs compared to traditional single-gene tests. Invitae's test offerings cover various hereditary conditions, including cancers, neurological disorders, cardiovascular diseases, pediatric and metabolic disorders. The company aims to make genetic testing more affordable and accessible, develop a secure infrastructure for genome management, and foster a global community for sharing genetic information to advance scientific research and medical practices. By lowering the barriers to obtaining diagnostic genetic information, Invitae seeks to improve healthcare outcomes for millions of individuals.
Foundation Medicine, Inc. specializes in providing molecular information products aimed at enhancing cancer treatment through genomic insights. The company utilizes proprietary methods and algorithms to analyze cancer specimens, helping physicians tailor treatments based on the unique genetic profile of each patient's tumor. Its product offerings include FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies, and various diagnostic assays such as FoundationFocus CDxBRCA for ovarian cancer. Additionally, Foundation Medicine develops a knowledgebase called FoundationCORE to disseminate scientific advancements within the oncology community. The company collaborates with major pharmaceutical firms and research organizations to advance precision medicine and develop companion diagnostics. Founded in 2009 and headquartered in Cambridge, Massachusetts, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc. It aims to transform cancer care by enabling personalized treatment strategies informed by detailed genomic profiling.